ADX-038, Sodio cloruro Galenica Senese 0,9% solvente per uso parenterale clinical trials

A Phase 2, Randomized, Masked, Placebo-Controlled Study of Subcutaneously Administered ADX-038 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

This study is looking at a new treatment called ADX-038 for a serious eye condition called geographic atrophy (GA), which is a late form of age-related macular degeneration (AMD). Researchers want to see if this treatment can slow down the growth of GA.